In order to investigate the analgesic effect of timing of administration of ketorolac 10 mg i.v., we recorded patient-controlled use of diamorphine at 2, 4 and 12 h after abdominal hysterectomy. In a randomized, double-blind trial, 30 patients received ketorolac before skin incision and 28 after skin closure. A control group of 32 patients did not receive ketorolac. We measured operative blood loss and assessed nausea, vomiting and pruritus. After 2 h of patient-controlled analgesia, the median cumulative diamorphine dose in the group given ketorolac before operation was less than that of the control group (95 % confidence interval 8-66 g kg
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; P : 0.01). There were no other statistically significant differences in diamorphine consumption between the groups. The frequency of nausea and vomiting was similar in all groups. Median blood loss in the group given ketorolac before operation exceeded that of the patients who did not receive ketorolac before operation (95 % confidence interval 20-149 ml; P : 0.01). We conclude that the diamorphine-sparing effect of ketorolac attributable to timing of administration was small, conferred no clinical benefit and was accompanied by increased bleeding. No patient given ketorolac complained of pruritus. (Br. J. Anaesth. 1995; 75: [15] [16] [17] [18] Several studies have shown that non-steroidal antiinflammatory drugs (NSAID) given before [1, 2] or after surgery [3, 4] reduce subsequent analgesic requirements. However, there are few studies designed to show if an analgesic given to pain-free patients before surgery reduces the total analgesic requirement more than the same drug given by the same route after surgery [5] .
Postoperative administration of ketorolac by i.m. infusion reduces morphine requirements by 33 % [3] . This may lessen troublesome symptoms such as nausea and pruritus. NSAID decrease in vitro platelet aggregation and increase skin bleeding time within 1 h of systemic administration [6] . Postoperative rather than preoperative administration may therefore minimize blood loss. It is thus desirable to know if the timing of administration of NSAID influences the opioid-sparing effect in a way that is clinically important.
The primary aim of this study was to compare the opioid-sparing effect of ketorolac given before with that after total abdominal hysterectomy. The secondary aim was to study the effect of timing of administration on operative blood loss, and the frequency of postoperative nausea, vomiting and pruritus.
Patients and methods
The study was approved by the local Ethics Committee and patients gave written informed consent. We considered consecutive patients presenting for total abdominal hysterectomy by transverse lower abdominal incision ard excluded those who were ASA III or IV, weighed less than 45 kg or more than 90 kg, had known malignancy, endometriosis, alcohol or drug addiction, chronic analgesic consumption, or any contraindication to ketorolac administration detailed by the Medicines Control Agency [7] .
The study was double-blind. The hospital pharmacy prepared solutions containing either 0.9 % normal saline 51 ml alone or 0.9 % normal saline 50 ml with ketorolac 10 mg (1 ml). They were labelled with a code held by the pharmacy until the end of the study. Each patient was given one infusion between induction of anaesthesia and skin incision, and another between skin closure and arrival in the recovery ward. Patients were allocated to one of three treatment groups by computer-generated random numbers in blocks of 12. One group was given ketorolac before and saline after operation. Another group was given saline before and ketorolac after operation. The third group was given saline both before and after operation, with no ketorolac.
All patients received a standard general anaesthetic. We prescribed oral temazepam 10-20 mg and metoclopramide 10 mg 90 min before operation. Anaesthesia was induced with thiopentone 3-5 mg kg Ϫ1 and vecuronium 0.1 mg kg Ϫ1 to facilitate tracheal intubation. Alfentanil was given as a bolus of 30 g kg 91 at induction. Anaesthesia was maintained with 1-1.5 % enflurane and 66 % nitrous oxide in oxygen. An infusion of alfentanil 40 g kg 91 h 91 was continued during surgery. Prochlorperazine 12.5 mg was given i.m. after induction of anaesthesia. Operative blood loss was estimated in a standard way by weighing swabs and measuring the volume of suction loss.
We prescribed patient-controlled analgesia (PCA) for all patients. The prescription was standard: diamorphine 60 mg in water 60 ml, with a 1-mg bolus and 5-min lock-out interval, no background infusion and no cumulative dose limit. We prescribed prochlorperazine 12.5 mg i.m. 6 hourly to a maximum of three doses, if required, for nausea and vomiting.
Data were collected for the first 12-h period of PCA. The cumulative dose of diamorphine at 2, 4 and 12 h was recorded. The incidence of nausea, vomiting and pruritus was noted, and the number of doses of prochlorperazine given in each group.
We estimated our sample size from a similarly designed trial using ketorolac 30 mg, which was aborted following the Medicines Control Agency publication which recommended an initial dose of 10 mg [7] . We assumed that the values for diamorphine doses would be normally distributed and that it would be of clinical importance to detect a difference of 100 g kg Ϫ1 in diamorphine use associated with timing of administration of ketorolac. In this aborted trial, mean diamorphine use over 12 h in the seven control patients who did not receive ketorolac was 410 (SD 110) g kg
Ϫ1
. We set the power of the study at 90 % with a type 1 error of 0.05. We estimated the minimum number of patients in each group as 26. We decided to study a total of 90 patients because it is difficult to ensure randomization into three groups of precisely equal size if some patients are withdrawn from the study after allocation of a trial number.
DATA ANALYSIS
The data were stored on Microsoft Excel and analysed statistically using Excel and Minitab. Chisquare tests were used to assess if the distribution of the blood loss measurements and diamorphine doses differed significantly from the normal distribution. As a consequence, Mann-Whitney tests were applied to differences in the cumulative doses of diamorphine and to differences in operative blood loss. The Fisher exact probability test was applied to the difference in the frequency of pruritus.
Results
Of the 157 patients scheduled for abdominal hysterectomy who were considered for inclusion in the trial, seven patients refused consent and 47 patients were excluded. After allocation of a trial number, 13 patients were later withdrawn; seven because a different operative procedure was performed, three because endometriosis was diagnosed at operation and three because of administrative errors in the conduct of the study. We report the results from 90 patients.
The ages and weights of the patients and the timing of events were similar in the three groups (table 1) . Four surgeons performed the majority of operations. The distribution of the surgeons between groups was similar.
The values for diamorphine use after 4 h of PCA in the group given ketorolac before operation were not normally distributed (chi square : 10.1, 4 df; P : 0.05). Table 2 shows the median, first quartile and third quartile cumulative diamorphine doses 2, 4 and 12 h after the start of PCA for each treatment group. At each time the median diamorphine dose was greatest in the control group and least in the group given ketorolac before operation. When these groups were compared, the 95 % confidence interval (P value) of the point estimate of the difference between the groups after 2 h of PCA was 8-66 g kg Ϫ1 (P : 0.01) (table 3) . There were no other statistically significant differences in diamorphine doses between the groups.
The procedure for blood loss measurement was successful in 29 of the 30 patients given ketorolac before skin incision and in 58 of the 60 patients who did not receive ketorolac before operation. The values for blood loss in the patients who did not receive ketorolac before operation were not distributed normally (chi square : 28.9, 9 df; P : 0.001). Median blood loss in the group given ketorolac before operation was 298 ml and of the remaining patients was 161 ml. The 95 % confidence interval of the Mann-Whitney point estimate of the difference between these groups was 20-149 ml (P : 0.01). The proportion of patients with blood loss of more than 600 ml was greater in the group given ketorolac before operation ( fig. 1 ). The increased bleeding associated with preoperative use of ketorolac had little effect on operating time (table 1) . There was no difference in the incidence of nausea or vomiting or in the use of prochlorperazine among the three groups (table 4) .
In the control group of 32 patients, six complained of pruritus, but no patient given ketorolac either before or after operation made this complaint. When the control group was compared with either of the two other groups, the difference in the frequency of pruritus was statistically significant (P : 0.03).
Discussion
There are few clinical studies comparing the effect of parenteral NSAID given before surgery with that given after surgery [5] . In a recent review [8] , the author's criteria for valid comparison of preoperative administration of an NSAID, with identical postoperative administration, were met by three studies [9] [10] [11] . These studies were undertaken in patients undergoing minor oral surgery, with the use of oral NSAID 15-30 min before operation or 30 min to 3 h after operation. None showed any pre-emptive effect, as measured by categorical and visual analogue pain intensity scales. In this review, the only study of the pre-emptive effect of NSAID in major surgery [12] was criticized because the design prevented analysis of the effectiveness of the timing of analgesic intervention [8] .
We chose ketorolac for our study because it is licensed for i.v. use. Following the report of the Medicines Control Agency on dose-related adverse reactions to ketorolac [7] , the dose was changed from 30 to 10 mg before starting the study afresh. A recent study of ketorolac 10 or 30 mg given after thoracotomy has shown similar efficacy for both doses [13] .
The assumption that opioid use data would be distributed normally was based on the common use of parametric tests to analyse these types of data. In the event, this assumption proved correct in all but one sample. However, because of this one departure, we used a non-parametric test.
Apart from the randomized, blind administration of ketorolac, we used a standard regimen of peroperative and postoperative analgesia. Alfentanil at the time and dose given has been shown not to influence requirements for postoperative analgesia [14] . Our study design included control patients who also received peroperative alfentanil, allowing us to investigate the opioid-sparing effect of ketorolac alone.
We found a significant reduction in opioid consumption 2 h after starting PCA, but not thereafter, in the group of patients given ketorolac before operation compared with the control group. When comparison was made between the groups given ketorolac, we found that the difference in opioid consumption was small and likely to be clinically unimportant.
We confirmed the finding of Engel and colleagues [2] that a NSAID given before hysterectomy was associated with increased blood loss.
The incidence of nausea and vomiting was similar in the three groups. In a similar study on the effect of ketorolac on postoperative opioid requirements and recovery, Parker, Holtmann and White [15] did not find a reduction in the incidence of nausea, vomiting or pruritus, despite the lower opioid use in the ketorolac group. However, they did find earlier return of bowel function in those patients given ketorolac; we did not study this aspect in our trial.
Interestingly, we found a significant difference in the incidence of pruritus. There were no complaints of this symptom in the groups receiving ketorolac. Others [16, 17] have reported similar findings and the observation merits further investigation. Figure 1 Percentage of patients in different blood loss categories given ketorolac before operation (n : 29) (!) and in 58 patients not given ketorolac before operation ("). 
